Atara Biotherapeutics (Nasdaq: ATRA) is an off-the-shelf, allogeneic T-cell immunotherapy company.
Atara Biotherapeutics has raised $550K in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2026.
Atara Biotherapeutics's investors include Kleiner Perkins, Redmile Group, EcoR1 Capital, Domain Associates, Panacea Venture.
Atara Biotherapeutics is headquartered in South San Francisco, United States.
Atara Biotherapeutics (Nasdaq: ATRA) is an off-the-shelf, allogeneic T-cell immunotherapy company.
Atara Biotherapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Atara Biotherapeutics — Funding & Investors." VCBacked, May 1, 2026, https://www.vcbacked.co/company/atara-biotherapeutics. Accessed July 20, 2026.
VCBacked. (2026). Atara Biotherapeutics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/atara-biotherapeutics
{{cite web |title=Atara Biotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/atara-biotherapeutics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated